The global hepatitis drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 12.42% through to 2015, driven by the increase in demand for hepatitis drugs in developing countries along with the increase in the number of mergers and acquisitions.
However, the shortage of hepatitis drugs to meet market demand could pose a challenge to the growth of this market.
Vendors are increasingly forming strategic alliances with other vendors to market their manufactured drugs to acquire a wider market share in the Global Hepatitis Drugs market. For instance Merck and Co. Inc. has formed a partnership with Roche Holding Ltd. to market its hepatitis drugs to increase its market share. Similarly, Vertex Pharmaceuticals Ltd. has a partnership with Johnson and Johnson Services Inc. to market its hepatitis drugs outside the US.
Key companies dominating the hepatitis drugs market include Abbott Laboratories, Bristol-Myers Squibb Co., Gilead Sciences Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Merck Co. Inc.
An experimental drug combination has just been released by Abbott Laboratories which wiped out all traces of the virus that causes hepatitis C in 99% of patients with the liver disease.
The 571 patients in the trial took a two- or three-drug mixture of Abbott therapies for 8 to 24 weeks, along with the antiviral ribavirin. A 79-patient group on the combination of three medicines plus ribavirin for 12 weeks responded best.
Follow us on Twitter @CandMResearch
